非洲、中南美洲和亚洲的癌症生存(SURVCAN-3):32个国家基于人群的基准研究
SURVCAN-3是一项国际协作,纳入32个国家68个基于人群的癌症登记处、1400435例2008至2012年诊断的癌症患者,计算15种主要癌症的1年、3年和5年年龄标化净生存率并按HDI分层。各国生存差异大,生存率随HDI水平升高而上升;不同癌种的HDI差异幅度不同。作者认为生存差异与国家发展水平及卫生服务可及性和效率相关。
要点
- 最低HDI国家(如科特迪瓦)前列腺癌3年净生存最高为54.6%,最高HDI国家(如以色列)为96.8%。
- 肺癌和胃癌3年净生存中位数低于30%且HDI间差异小。
- 宫颈癌和结直肠癌3年净生存中位数为30-79%且HDI间差异中等。
核心结论
- 各国癌症生存差异与国家发展水平及卫生服务的可及性和效率相关,数据可帮助政策制定者确定癌症控制重点以减少结局不平等。
研究设计与样本
- SURVCAN-3为基于人群癌症登记处的国际协作基准研究。
- 纳入非洲、中南美洲和亚洲32个国家68个登记处、2008年1月1日至2012年12月31日诊断并随访至少2年(至2014年12月31日)的1400435例癌症患者。
- 采用Pohar-Perme估计量计算15种主要癌症诊断后1年、3年和5年的年龄标化净生存率及95%CI。
- 生存估计按洲内国家和四层HDI(低、中、高、极高)分层。
主要发现
- 各国和世界区域间净生存差异大,估计值随HDI水平升高而稳步上升。
- 最低HDI类别国家(如科特迪瓦)3年净生存最高为54.6%(95%CI 33.3-71.6;前列腺癌)。
- 最高HDI类别国家(如以色列)3年净生存最高为96.8%(95%CI 96.1-97.3;前列腺癌)。
- 按癌种和HDI识别出三组结局:肺癌和胃癌等3年净生存中位数低于30%且HDI间差异小;宫颈癌和结直肠癌等中位数为30-79%且HDI间差异中等;乳腺癌和前列腺癌等中位数不低于80%且HDI间差异大。
关键数值与推荐
- 最低HDI类别国家(如科特迪瓦)前列腺癌3年净生存最高为54.6%(95%CI 33.3-71.6)。
- 最高HDI类别国家(如以色列)前列腺癌3年净生存最高为96.8%(95%CI 96.1-97.3)。
- 3年净生存中位数低于30%且HDI间差异小的癌种包括肺癌和胃癌。
- 3年净生存中位数为30-79%且HDI间差异中等的癌种包括宫颈癌和结直肠癌。
- 3年净生存中位数不低于80%且HDI间差异大的癌种包括乳腺癌和前列腺癌。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Population-based cancer survival is a key measurement of cancer control performance linked to diagnosis and treatment, but benchmarking studies that include lower-income settings and that link results to health systems and human development are scarce. SURVCAN-3 is an international collaboration of population-based cancer registries that aims to benchmark timely and comparable cancer survival estimates in Africa, central and south America, and Asia. METHODS: In SURVCAN-3, population-based cancer registries from Africa, central and south America, and Asia were invited to contribute data. Quality control and data checks were carried out in collaboration with population-based cancer registries and, where applicable, active follow-up was performed at the registry. Patient-level data (sex, age at diagnosis, date of diagnosis, morphology and topography, stage, vital status, and date of death or last contact) were included, comprising patients diagnosed between Jan 1, 2008, and Dec 31, 2012, and followed up for at least 2 years (until Dec 31, 2014). Age-standardised net survival (survival where cancer was the only possible cause of death), with 95% CIs, at 1 year, 3 years, and 5 years after diagnosis were calculated using Pohar-Perme estimators for 15 major cancers. 1-year, 3-year, and 5-year net survival estimates were stratified by countries within continents (Africa, central and south America, and Asia), and countries according to the four-tier Human Development Index (HDI; low, medium, high, and very high). FINDINGS: 1 400 435 cancer cases from 68 population-based cancer registries in 32 countries were included. Net survival varied substantially between countries and world regions, with estimates steadily rising with increasing levels of the HDI. Across the included cancer types, countries within the lowest HDI category (eg, CÔte d'Ivoire) had a maximum 3-year net survival of 54·6% (95% CI 33·3-71·6; prostate cancer), whereas those within the highest HDI categories (eg, Israel) had a maximum survival of 96·8% (96·1-97·3; prostate cancer). Three distinct groups with varying outcomes by country and HDI dependant on cancer type were identified: cancers with low median 3-year net survival (<30%) and small differences by HDI category (eg, lung and stomach), cancers with intermediate median 3-year net survival (30-79%) and moderate difference by HDI (eg, cervix and colorectum), and cancers with high median 3-year net survival (≥80%) and large difference by HDI (eg, breast and prostate). INTERPRETATION: Disparities in cancer survival across countries were linked to a country's developmental position, and the availability and efficiency of health services. These data can inform policy makers on priorities in cancer control to reduce apparent inequality in cancer outcome. FUNDING: Tata Memorial Hospital, the Martin-Luther-University Halle-Wittenberg, and the International Agency for Research on Cancer.
引用
- Soerjomataram I, Cabasag C, Bardot A, et al. Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries. Lancet Oncol. 2023. PMID: 36603919. doi:10.1016/S1470-2045(22)00704-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。